top of page
—Pngtree—pink ribbon flow breast cancer_4017964_edited.png
HEADERS_edited_edited.png

The links below should help answer the questions like..  what is it?,  what does that mean? 

IMG_3431.JPG

Invasive ductal carcinoma (IDC)

​

 (IDC), sometimes called infiltrating ductal carcinoma, is the most common type of breast cancer. About 80% of all breast cancers are invasive ductal carcinomas.

Invasive means that the cancer has “invaded” or spread to the surrounding breast tissues. Ductal means that the cancer began in the milk ducts, which are the “pipes” that carry milk from the milk-producing lobules to the nipple. Carcinoma refers to any cancer that begins in the skin or other tissues that cover internal organs — such as breast tissue. All together, “invasive ductal carcinoma” refers to cancer that has broken through the wall of the milk duct and begun to invade the tissues of the breast. Over time, invasive ductal carcinoma can spread to the lymph nodes and possibly to other areas of the body.

According to the American Cancer Society, more than 180,000 women in the United States find out they have invasive breast cancer each year. Most of them are diagnosed with invasive ductal carcinoma.

Although invasive ductal carcinoma can affect women at any age, it is more common as women grow older. According to the American Cancer Society, about two-thirds of women are 55 or older when they are diagnosed with an invasive breast cancer. Invasive ductal carcinoma also affects men.

What Does Stage 2 Breast Cancer Mean and What’s the Prognosis?

 

If you have stage 2 breast cancer, it means that the cancer hasn’t spread beyond the breast tissue or nearby lymph nodes.

Cancer isn’t a single disease. It’s a group of diseases, and breast cancer is no different. Because there are different types, not all stage 2 breast cancers are treated the same way.

In this article, we’ll explore how breast cancer is staged and treated, as well as the general outlook.

 

What is stage 2 breast cancer? 

When it’s first confirmed that you have breast cancer, your doctor will assign a clinical stage to your cancer diagnosis. This is called clinical staging and it’s based on: 

  • a physical exam

  • imaging tests

  • biopsy results

If surgery is done to examine the breast tissue, laboratory test results on the tissue and lymph nodes will be able to provide more information. Based on these results, your doctor will be able to determine the pathologic stage, or surgical stage, of the cancer. This is more accurate than the clinical stage.

Breast cancer staging involves the TNM system, which provides specific details about: 

  • T: the size of the tumor

  • N: lymph node involvement

  • M: whether the cancer has spread (metastasized)

The size of primary tumor (T)

T followed by a number is an indication of the size of the primary tumor. A higher number means a larger tumor.

  • TX: the tumor can’t be measured

  • T0: primary tumor can’t be located

  • T1, T2, T3, T4: size of the tumor from smallest to largest

Lymph node involvement (N)

N followed by a number tells you whether the cancer has spread to lymph nodes. If so, the number indicates how many lymph nodes the cancer cells have spread to. 

  • NX: cancer cells in nearby nodes can’t be measured

  • N0: cancer has not spread to nearby nodes

  • N1, N2, N3: number of nodes that contain cancer

Metastasis (M)

This is an indication of whether the cancer cells have spread to other organs in the body. 

  • M0: there’s no sign that cancer has spread to other parts of the body (stage 2 breast cancer is always M0)

  • MX: spread can’t be measured

  • M1: cancer has spread to other parts of the body, like the lungs, liver, or bones

These factors are combined to determine the cancer stage. Breast cancer is staged from 1 to 4. 

Stage 2 breast cancer has two subcategories.

 
Stage 2A

Breast cancer is stage 2A if one of these is true:

  • There’s no tumor in the breast, but breast cancer cells are found in nearby lymph nodes.

  • The primary tumor is 2 centimeters (cm) or smaller and cancer cells are found in fewer than 4 of the axillary lymph nodes. 

  • The breast tumor is between 2 and 5 cm, but there’s no lymph node involvement.

​

Stage 2B

Breast cancer is stage 2B if one of these is true:

  • The breast tumor is between 2 and 5 cm and the cancer has reached 4 or fewer lymph nodes.

  • The tumor is over 5 cm but there’s no lymph node involvement.

Share on Pinterest

Stage 2B breast cancer

​

Additional considerations

Breast cancer staging is complicated. There are a few other factors that can affect the overall staging diagnosis, including a tumor grading system and the presence of certain receptors in breast cancer cells.

A tumor grading system provides an indication of how fast cancer cells are likely to grow and spread. At higher grades, the cancer is considered more aggressive.

Tumor grading
  • G1: well differentiated, or low grade

  • G2: moderately differentiated, or intermediate grade

  • G3: poorly differentiated, or high grade

In addition, the tumor will be tested for receptors that can affect your treatment options and provide a better idea of what to expect. 

Receptor status
  • estrogen receptor (ER) status: ER+ or ER-

  • progesterone receptor (PR) status: PR+ or PR-

  • HER2 status (a growth-promoting protein found on the outside of breast cells): HER2+ or HER2-

ER and PR status are sometimes referred to as hormone receptor (HR) status.

These factors can also be used in staging because these cancers behave differently. For example: 

  • HR+/HER2- breast cancer is generally slow-growing and less aggressive than other types.

  • HR-/HER2-, also known as triple-negative, tends to be more aggressive.

  • HR+ or -/HER2+ is another type that can be aggressive.

The bottom line 

In stage 2 breast cancer, cancer cells have not spread beyond the breast or nearby lymph nodes. Knowing the HR and HER2 status of your stage 2 breast cancer can help your oncologist determine which treatments are most likely to be effective.

Stage 2 breast cancer is very treatable and the overall outlook is good. As with most types of cancer, the earlier your cancer is diagnosed and treated, the better the outcome.

What type of treatment can you expect? 

 

The tumor’s HR and HER2 status will determine some of your treatment options. Your doctor will also consider: 

  • any other health conditions you may have

  • your age

  • your menopausal status

Typically, treatment involves a combination of therapies. Here’s a look at some of the most common types of treatment for stage 2 breast cancer.

Surgery

Depending on the size and location of the tumor, surgical options may include:

  • breast-conserving surgery (lumpectomy)

  • modified radical mastectomy with or without reconstruction

During both of these procedures, the surgeon will also perform a sentinel lymph node biopsy to see if the cancer has spread.

Radiation therapy

Radiation therapy typically follows surgery, especially if you have a lumpectomy. 

If you have a mastectomy, certain factors will help determine whether you need radiation treatment. These factors include:

  • the size of the tumor

  • the number of lymph nodes to which the cancer has spread

Radiation is used to lower the chances of recurrence. Radiation therapy works by damaging the DNA of cancer cells. This helps to destroy them.

Radiation therapy is typically a localized type of treatment. This means it’s only targeted at the specific area that is radiated. It doesn’t target your whole body like chemotherapy or some types of medication.

There are various forms of radiation. Some regimens are 5 days, some are 3 to 4 weeks, and some are 5 to 6 weeks long. 

The most common side effects include fatigue, as well as redness, skin peeling, and swelling around the area that’s being treated.

Chemotherapy

Chemotherapy can be used to shrink tumors before surgery or to lower the chance of recurrence after surgery. 

There are fewer treatment options for triple-negative breast cancer since it doesn’t have HR or HER2 receptors. But it tends to respond well to chemotherapy.

For breast cancer, chemotherapy drugs are usually given through a vein intravenously (IV). This may be as an injection that lasts several minutes, or as an infusion that lasts for hours or longer. 

Chemotherapy for breast cancer is typically given in cycles of about 1 or 2 to 3 weeks. You’ll be given chemotherapy through an IV on one day of the week, or for a few days in a row. You’ll then be given time to recover from the drugs before starting your next cycle. 

One of the disadvantages of chemotherapy is that these drugs can’t tell cancerous cells from healthy cells. As a result, some healthy cells can get temporarily damaged in addition to cancerous ones. This can result in side effects such as:

  • nausea

  • hair loss

  • fatigue

  • mouth sores

  • loss of appetite

  • diarrhea or constipation

Some types of chemotherapy may also cause early menopause. 

Targeted therapy

Targeted or biologic therapies involve the use of drugs that can tell the difference between cancer cells and normal cells a little better than chemotherapy. These drugs have the ability to affect cancer cells, sometimes with less harm to other cells.

Targeted therapies are a newer treatment approach and new drugs are being developed as scientists learn more about how cancer cells grow and multiply, and what differentiates them from normal cells. 

For stage 2 breast cancer, targeted hormone therapy can be effective for estrogen receptor-positive (ER+) or progesterone receptor-positive (PR+) cancers. Therapies may include:

  • tamoxifen

  • anastrozole

  • exemestane

  • letrozole

Side effects of hormone therapy can include hot flashes and vaginal dryness. 

Other types of targeted therapy have the ability to detect certain proteins or enzymes associated with cancer cells. For instance, with HER2-positive breast cancer, targeted therapy can disrupt the high levels of growth-promoting protein on the surface of the cancer cells. 

Some therapies for stage 2 HER2-positive breast cancer include:

  • trastuzumab

  • pertuzumab

  • ado-trastuzumab emtansine

  • neratinib

​

What happens after treatment? 

Follow-up care

Once primary treatment ends, hormone therapy can continue anywhere from 5 to 15 years. And breast reconstruction may be a multi-step process that takes many months. 

Your first post-treatment visit will probably be within a few months. Your doctor will want to see how you’re doing and if you need help with the side effects of treatment. Eventually, you’ll transition to visits every 6 months, then yearly visits. Yearly checkups will include breast imaging.

Your doctor will work out a schedule based on the level of care you need. 

Emotional care

Coming to the end of your treatment can be a challenging transition. Emotions can range from relief and exhilaration to anxiety and sadness. Fear of recurrence is common. These emotions and fears are all perfectly normal.

When your focus has been on treatment, side effects, and scheduling appointments, it can take a little time to get used to life on the other side of those details.

Also, loved ones may be so happy for you that they don’t realize you’re still dealing with the physical and emotional effects of your cancer treatment. You don’t have to live up to anyone’s expectations but your own. When or if you get back to your old routine depends on circumstances unique to you. 

It’s important to follow your own timetable and to do things at a pace that works for you.

What’s the survival rate?

Overall, the prognosis for stage 2 breast cancer is generally good. According to the American Cancer Society, the 5-year relative survival rate is:

  • 99 percent for localized breast cancer (has not spread outside the breast)

  • 86 percent for regional breast cancer (spread to nearby lymph nodes)

These figures represent those who received diagnoses between 2010 and 2016, before some new targeted therapies were available. In addition, these percentages vary somewhat based on ER/PR and HER2 status. 

Certain types of breast cancer have a better prognosis than others. 

This may be because some, such as HR+/HER2-, are more responsive to hormonal therapy, and HER2-positive breast cancers are responsive to anti-HER2 targeted therapy. Some, like triple-negative breast cancers, have fewer treatment options and a higher recurrence rate in the first few years.

Your oncologist can review your complete medical profile to give you a better idea of what to expect.

invasive ductal carcinoma
What is stage 2B
Screen Shot 2021-09-26 at 12.02.14 AM.png
Treatment
,lisa 2.png
bottom of page